Format

Send to

Choose Destination
See comment in PubMed Commons below
Antiviral Res. 2013 Dec;100(3):640-8. doi: 10.1016/j.antiviral.2013.10.003. Epub 2013 Oct 20.

Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis.

Author information

1
Institute for Clinical and Molecular Virology, University of Erlangen-Nuremberg, Erlangen, Germany. Electronic address: manfred.marschall@viro.med.uni-erlangen.de.

Abstract

Currently available antiviral drugs frequently induce side-effects or selection of drug-resistant viruses. We describe a novel antiviral principle based on targeting the cellular enzyme dihydroorotate dehydrogenase (DHODH). In silico drug design and biochemical evaluation identified Compound 1 (Cmp1) as a selective inhibitor of human DHODH in vitro (IC50 1.5±0.2nM). Crystallization data specified the mode of drug-target interaction. Importantly, Cmp1 displayed a very potent antiviral activity that could be reversed by co-application of uridine or other pyrimidine precursors, underlining the postulated DHODH-directed mode of activity. Human and animal cytomegaloviruses as well as adenoviruses showed strong sensitivity towards Cmp1 in cell culture-based infection systems with IC50 values in the low micromolar to nanomolar range. Particularly, broad inhibitory activity was demonstrated for various types of laboratory and clinically relevant adenoviruses. For replication of human cytomegalovirus in primary fibroblasts, antiviral mode of activity was attributed to the early stage of gene expression. A mouse in vivo model proved reduced replication of murine cytomegalovirus in various organs upon Cmp1 treatment. These findings suggested Cmp1 as drug candidate and validated DHODH as a promising cellular target for antiviral therapy.

KEYWORDS:

4SCan drug design; Antiviral drug candidate; Broad-spectrum antiviral therapy; Cytomegaloviruses and adenoviruses; Pyrimidine biosynthesis; Target dihydroorotate dehydrogenase

PMID:
24149002
DOI:
10.1016/j.antiviral.2013.10.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center